Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist for renal anemia, physicians, patients, and healthcare systems are concerned over some aspects of the current therapies. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of renal anemia therapies such as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). This content examines the management of dialysis and mid- to late-stage CKD patients from the perspective of nephrologists. It provides a detailed and expanded analysis of renal anemia market dynamics, and insight into practice patterns, physician attitudes and perceptions, and current and projected use of various renal anemia therapies such as Epogen, Aranesp, Procrit, Injectafer, and Venofer, as well as new therapies such as Mircera and Triferic. Also included in this content are persistency, compliance, and drivers and obstacles to the use of various renal anemia medications.
- Why do nephrologists switch their patients from IV iron to ESAs?
- At what hemoglobin levels do nephrologists typically initiate ESA therapy?
- Will Amgen’s Epogen hold on to its lead in the dialysis market, or will Roche’s Mircera take over?
- How will Rockwell Medical’s Triferic perform in the dialysis population?
- Do dialysis centers influence renal anemia treatment decisions?
Current Treatment: Provides physician insights on prescribing behavior and treatment paths and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.